Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

Monoclonal antibodies (mAbs) deliver great benefits to patients with chronic and/or severe diseases thanks to their strong specificity to the therapeutic target. As a result of this specificity, non-human primates (NHP) are often the only preclinical species in which therapeutic antibodies cross-rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ménochet, Karelle, Yu, Hongbin, Wang, Bonnie, Tibbitts, Jay, Hsu, Cheng-Pang, Kamath, Amrita V., Richter, Wolfgang F., Baumann, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704389/
https://www.ncbi.nlm.nih.gov/pubmed/36418217
http://dx.doi.org/10.1080/19420862.2022.2145997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704389/
https://www.ncbi.nlm.nih.gov/pubmed/36418217
http://dx.doi.org/10.1080/19420862.2022.2145997

Ejemplares similares